Valuation: Pulmonx Corporation

Market Cap 110M 97.97M 89.61M 81.61M 154M 10.39B 158M 1.08B 430M 5.5B 413M 404M 17.36B P/E 2026 *
-2.64x
P/E 2027 * -2.9x
Enterprise Value 110M 97.97M 89.61M 81.61M 154M 10.39B 158M 1.08B 430M 5.5B 413M 404M 17.36B EV / Sales 2026 *
1.21x
EV / Sales 2027 * 1.12x
Free-Float
95.42%
Yield 2026 *
-
Yield 2027 * -
1 day+2.93%
1 week-12.81%
Current month-12.81%
1 month+47.19%
3 months+27.80%
6 months+103.10%
Current year+18.55%
1 week 2.48
Extreme 2.48
3.13
1 month 1.72
Extreme 1.72
3.25
Current year 1.13
Extreme 1.13
3.25
1 year 1.13
Extreme 1.13
3.25
3 years 1.13
Extreme 1.13
14.84
5 years 1.13
Extreme 1.13
45.49
10 years 1.13
Extreme 1.13
69.48
Manager TitleAgeSince
Chief Executive Officer 64 27/10/2025
Director of Finance/CFO 53 01/05/2019
Chief Tech/Sci/R&D Officer - 01/03/2020
Director TitleAgeSince
Director/Board Member 72 01/02/2007
Chairman 66 01/10/2019
Director/Board Member 64 18/12/2014
Date Insider Type Main position Quantity % Market Cap. Importance
1/9/26 Sell

Chief Technology Officer

-14,245 0.0332%
1/9/26 Sell

Chief Executive Officer

-41,882 0.0975%
1/9/26 Sell

Executive/Senior Manager

-7,879 0.0183%
Change 5-day change 1-year change 3-year change Capi.($)
+2.93%-12.81%+44.75%-72.74% 110M
-2.32%+4.67%-11.04%+17.01% 197B
-2.53%+11.94%-7.66%+18.02% 128B
-2.28%+6.13%+13.77%+39.55% 128B
+0.96%+5.15%-38.02%+12.24% 99B
-1.60%+0.88%-7.35%+69.52% 64.82B
+0.09%+8.05%+20.53%-17.48% 58.17B
+1.06%+22.10%-5.71%+59.10% 52.84B
-6.98%-14.94%-9.70%+46.32% 50.69B
-2.36%+4.26%+3.81%-7.59% 37.23B
Average -1.30%+4.42%+0.34%+16.40% 81.55B
Weighted average by Cap. -1.82%+7.56%-6.22%+25.26%

Financials

2026 *2027 *
Net sales 91.03M 81.12M 74.2M 67.58M 127M 8.6B 131M 891M 356M 4.56B 342M 334M 14.38B 98.6M 87.86M 80.36M 73.19M 138M 9.32B 142M 965M 386M 4.93B 370M 362M 15.57B
Net income -41.31M -36.81M -33.67M -30.66M -57.8M -3.9B -59.35M -404M -162M -2.07B -155M -152M -6.52B -40.16M -35.78M -32.73M -29.81M -56.19M -3.79B -57.7M -393M -157M -2.01B -151M -147M -6.34B
Net Debt - -
Projected Income Statement - Annual - Pulmonx Corporation
Logo Pulmonx Corporation
Pulmonx Corporation is a commercial-stage medical technology company. The Company provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.
Employees
296
Date Price Change Volume
07/11/26 US$2.635 +2.93% 213,200
05/11/26 US$2.560 -9.54% 742,450
04/11/26 US$2.830 +4.04% 984,142
03/11/26 US$2.720 +5.43% 744,084
02/11/26 US$2.580 -14.14% 1,437,254
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Pulmonx Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.560USD
Average target price
3.700USD
Spread / Average Target
+44.53%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Pulmonx Corporation
  1. Stock Market
  2. Stocks
  3. LUNG Stock